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Abstract
Blasts from different patients with acute myeloid leukemia (AML) vary in the agent(s) to
which they are most responsive. With a myriad of novel agents to evaluate, there is a lack of
predictive biomarkers to precisely assign targeted therapies to individual patients. Primary
AML cells often survive poorly in vitro, thus confounding conventional cytotoxicity assays.
The purpose of this work was to assess the potential of two same-day functional predictive
assays in AML cell lines to predict long-term response to chemotherapy. (i) Ribosomal pro-
tein S6 (rpS6) is a downstream substrate of PI3K/akt/mTOR/ kinase and MAPK kinase path-
ways and its dephosphorylation is also triggered by DNA double strand breaks. Phospho-
rpS6 is reliably measurable by flow cytometry and thus has the potential to function as a bio-
marker of responsiveness to several therapeutic agents. (ii) A cell’s propensity for apoptosis
can be interrogated via a functional assay termed “Dynamic BH3 Profiling” in which mito-
chondrial outer membrane permeabilization in drug-treated cells can be driven by pro-apo-
ptotic BH3 domain peptides such as PUMA-BH3. The extent to which a particular cell is
primed for apoptosis by the drug can be determined by measuring the amount of cyto-
chrome C released on addition of BH3 peptide. We demonstrate that phospho-rpS6 expres-
sion and PUMA-BH3 peptide-induced cytochrome C release after 4 hours both predict long
term chemoresponsiveness to tyrosine kinase inhibitors and DNA double strand break
inducers in AML cell lines. We also describe changes in expression levels of the prosurvival
BCL-2 family member Mcl-1 and the pro-apoptotic protein BIM after short term drug culture.
Introduction
AML is a heterogeneous clonal disorder of haemopoietic progenitor cells where both failure to
differentiate and over proliferation results in accumulation of non-functional cells termed
myeloblasts.[1] While nearly 80% of younger AML patients may initially achieve complete
remission with current therapy, most will relapse with resistant disease.[2] Clinical outcomes
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in the elderly are even more modest as these patients do not tend to tolerate intensive chemo-
therapy regimens and frequently have adverse cytogenetics.[1]
There are many obstacles a chemotherapeutic drug has to circumvent before it can kill a
leukaemia cell. Briefly, the drug has to reach its target, initiate the appropriate pro-apoptotic
signals and overcome the cell’s anti-apoptotic defences. Despite the abundance of novel agents
that have the potential to improve patient outcome, we are still lacking assays that clinicians
can be offered to demonstrate which drugs the individual patient will best respond to. Most
efforts in assigning therapy involve predicting a patient’s response to an agent based on their
cytogenetic profile. The obvious solution might be chemosensitivity assays, but these have
been tried, tested and found wanting.[3, 4] A confounding issue is that cells can be fragile ex
vivo, and most AML cells will die spontaneously in culture fairly quickly (median survival at
48 hours = 38% of baseline).[5] Assays have been developed to maintain leukaemia cells in
vitro, but AML samples are so heterogeneous that there is no “one-size-fits all” methodology
for keeping them alive once they have been isolated from the patient. By focusing on same-day
assays, with intact cells, we hope to overcome this obstacle.
Ribosomal protein S6 is a downstream substrate of PI3K/akt/mTOR/ p70S6 kinase and
MAPK/p90S6 kinase pathways and is also dephosphorylated following DNA double strand
breaks.[6–10] RpS6 is a constituent of the 40S ribosomal subunit that is phosphorylated at sev-
eral sites including serines 235/236 and 240/244 upon activation by p70S6 and p90S6 kinases.
[6] Phosphorylation of rpS6 controls mRNA translation in dividing cells,[11] and its recruit-
ment to the 7-methylguanosine cap structure suggests a role in regulating assembly of the
translation preinitiation complex.[8] The AKT and/or MAPK signalling pathways are consti-
tutively active in the majority of AML cases.[12, 13] We have recently determined that rpS6 is
hyperphosphorylated in AML patient samples, with phosphorylation being over 20 fold higher
than in normal mobilised CD34+ cells.[14] Moreover, rpS6 phosphosrylation in patient sam-
ples can be abrogated by AKT and/or ERK inhibitors.[15] Some types of AML therapy, such as
DNA damaging agents and receptor kinase inhibitors, might be expected to converge to
dephosphorylate rpS6 through their actions on the akt/mTOR, ATM/AMPK/mTOR and/or
ERK pathways.[9, 16] Phosphorylated rpS6 is therefore a potential biomarker of responsive-
ness to several therapeutic agents. Antibodies to rpS6 phosphorylated at serine 235/236 have
been optimised for flow cytometry, where they are well-established as biomarkers for
mTORC1 activity.[17, 18]
The B-Cell Lymphoma-2 (Bcl-2) family of proteins act at the mitochondria and regulate the
internal apoptotic pathway. For apoptosis to occur, the proapoptotic effector molecules BAK
and BAXmust oligomerise and form pores that cause mitochondrial outer membrane permea-
bilisation (MOMP) resulting in cytochrome c release. Effector molecule activation can be trig-
gered by BH3-only proapoptotic BCL-2 family members such as PUMA, BIM and BID.[19]
These pro-apoptotic family members are usually sequestered by BCL-2 family prosurvival
members such as MCL-1, BCL-2, and BCL-XL which serves to hold apoptosis in check.[20] A
cell’s propensity for apoptosis can be interrogated via a functional assay termed “Dynamic
BH3 Profiling”.[21] Dynamic BH3 profiling can predict cellular responses to therapy based on
measuring the capacity of drugs to prime mitochondria for apoptosis. The technique involves
the addition of permeable pro-apoptotic BH3 peptides to drug primed cells to induce rapid
mitochondrial outer membrane permeabilisation. The extent to which a particular cell is
primed for apoptosis can be determined by measuring the amount of cytochrome c released.
[22] Dynamic BH3 profiling using imatinib (with a 16 hour incubation) was found to predict
clinical responsiveness in CML patients.[21]
In this study we assess whether short term (4 hour) rpS6 de-phosphorylation and/or
PUMA-BH3 peptide-driven cytochrome c release can predict long-term (48 hour) response to
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chemotherapeutic drugs. As primary AML cells are unstable in vitro we utilize a panel of AML
cell lines in order to obtain robust 48 hour IC50 values for reliable comparison with the short
term functional assays. We also investigate whether drug exposure induces rapid changes in
expression levels of Bcl-2 protein family members.
Materials and methods
Materials
Drugs and suppliers used in the study were as follows: 17-AAG, rapamycin, sorafenib, U0126
and torin 1 from LC labs (www.lclabs.com); AC220 and vosaroxin from Selleck (supplied by
Stratech UK); etoposide from Tocris; gemtuzumab ozogamicin (GO) was a gift fromWyeth,
Pearl River USA. C2 ceramide and Calyculin A were from Santa Cruz Biotechnology, Santa
Cruz, CA, USA. Ly294006 was fromMillipore, Watford, UK. Other drugs and reagents were
from Sigma (Poole, Dorset, UK) unless specified.
Cells
OCI-AML3, MOLM-13 and M-07e myeloid leukaemia cell lines were obtained from the Ger-
man Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany).
U937 and KG1a cell lines were from the European Collection of Animal Cell Cultures (Salis-
bury, UK). MV4-11 and TF-1a cells were obtained from the American Type Culture Collection
(Manassas, VA, USA). HL-60 cells were a gift from Dawn Bradbury (Nottingham University
Hospitals, UK), OCI-AML6.2 cells were a gift from Dr. Jo Mountford (University of Glasgow,
UK), M0-91 cells were a gift from Joseph Scandura (Cornell Medical College, USA). OCI-
AMLDNR cells were developed in our laboratory.[23] HL-60, U937, OCI-AML3, OCI-AML
DNR, OCI-AML6.2, MOLM-13, TF-1a, M0-91 and MV4-11 cell lines were maintained in
RPMI 1640 medium with 10% foetal calf serum (FCS; First Link, Birmingham, UK), 2mM
L-glutamine, 100 U/ml penicillin and 10μg/ml streptomycin. The KG1a andM-07e cell lines
were maintained as above with 20% FCS and the M-07e having the addition of 10ng/ml
GM-CSF (Novartis, Basel, Switzerland). All cultures were kept at 37˚C in 5% CO2 and all exper-
iments were performed with cell lines in log phase. Regular testing to authenticate these cell
lines was performed using multiplex short tandem repeat analysis (Powerplex 16; Promega,
Southampton, UK). Mycoplasma testing was carried out routinely using the Mycoalert myco-
plasma detection kit (Lonza, Rockland, USA) and following the manufacturer’s instructions.
Chemosensitivity assay
Cells were plated in triplicate at 2.5x105/ml with drug or untreated controls in 96 well plates.
Plates were incubated for 48 hours at 37˚C in 5% CO2 with the addition of alamar blue (Sero-
tec, BUF012A) for the final 4 hours. Fluorescence was recorded using a POLARstar optima
plate reader (BMG technologies, UK). Cell lines were deemed sensitive or resistant to each
agent using the following criteria (<5 X 10th centile IC50 = sensitive;>5 X 10
th centile IC50 =
resistant).
Phospho-S6 ribosomal protein expression
Cells were incubated at 5x105/ml in culture medium for four hours with the indicated drugs.
Phospho-S6 ribosomal protein expression (using Alexa-647-conjugated rpS6 p-ser235/236
antibody, CST #4851) was measured following fixation in 2% paraformaldehyde and permea-
bilisation with 0.1% saponin as described.[14] Baseline rpS6 phosphorylation was determined
by culturing with the mTOR inhibitors rapamycin (100 nM) and torin1 (1 μM) and the ERK
Early predictors of AML chemosensitivity
PLOS ONE | https://doi.org/10.1371/journal.pone.0196805 May 3, 2018 3 / 16
inhibitor U0126 (3 μM). Adjustments for baseline rpS6 phosphorylation and expression in
untreated cells were made using the calculation %rpS6 dephosphorylation = 100 - 100X (MFI
with agent–baseline MFI)/(untreated MFI–baseline MFI), where MFI = mean fluorescence
intensity.
Dynamic BH3 profiling
Cells were incubated at 5x105/ml in culture medium for four hours with the indicated drugs.
Cytochrome c release (using Alexa-647-conjugated cytochrome c antibody, Becton Dickinson
#558709) was measured after a further 60 minute incubation of digitonin-permeabilised cells
with PUMA-BH3 peptide as described.[22, 24] In preliminary assays, the PUMA-BH3 was
optimised to 3 μM in all cells except M-091, as this was the concentration of the peptide found
to be sufficient to induce mitochondrial outer membrane permeabilisation in drug-primed
cells, but not so high that it induced a high degree of mitochondrial outer membrane permea-
bilisation without drugs. In M-091, the peptide was used at 0.5 μM. Adjustments for peptide-
induced cytochrome c release in untreated cells were made in order to establish agent-specific
release, using the formula 100X (percent cytochrome c positive with peptide–percent cyto-
chrome c positive with drug plus peptide)/(percent cytochrome c positive with peptide). A
mutated PUMA-BH3 peptide (PUMA2A) [22] at 100 μM and BIM-BH3 peptide (10 μM) were
used as controls in all experiments. Data were collected on a FACSCanto II flow cytometer
(Becton Dickinson) and analysed with FACS Diva software (Becton Dickinson).
Western blot analysis
MV4-11 cells were treated for four hours with 1 μM etoposide, 10 nM AC220 or 1 μM torin1.
Cell lysates were prepared, separated by sodium dodecyl sulfate polyacrylamide gel electropho-
resis, and transferred to nitrocellulose membranes. Detection antibodies included anti-Č-Actin
(N-21, sc-130656), anti-MCL1 (S-19, sc-819) and anti-Bcl-2 (C-2, sc-7382) from Santa Cruz
Biotechnology, Santa Cruz, CA, USA, anti-BID (#2002, Cell Signalling Technology, Leiden,
Netherlands), anti-BIM (Y36, ab32158), anti-BAD (phospho S136, ab28824) and anti-PUMA
(EP512Y, ab33906) from Abcam, Cambridge, UK.
Calculations and statistics
Statistical analysis was carried out using the Statistical Package for Social Sciences, version 23
(SPSS, Chicago, IL, USA). P values of0.05 were considered to represent significance. Area
under curve (AUC) receiver-operating characteristic (ROC) predictive analysis was used to
evaluate the relationship between sensitivity of cell lines to an agent and rpS6 phosphorylation
or cytochrome c release.[25]
Results
Multiple signalling pathways converge on rpS6 phosphorylation
The MAPK and/or AKT signalling pathways are constitutively active in the majority of AML
cases.[12, 13] RpS6 is a downstream mediator of both pathways,[7, 8] and is constitutively
phosphorylated in patient samples.[14] P-rpS6 has been used previously as a sensitive marker
for mTORC1 activation in flow cytometric studies.[15, 17, 18] To examine basal phosphoryla-
tion and inhibitor-induced dephosphoryation of rpS6 in our assay system, we cultured MV4-
11s for 4 hours with the mTORC1 inhibitor torin1, the ERK inhibitor U0126 and the akt inhib-
itor LY294002. All these agents were able to greatly reduce rpS6 phosphorylation (Fig 1). The
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Fig 1. RpS6 dephosphorylation by signalling inhibitors. (A)MV4-11 cells were cultured for 4 hours with 1 μM torin1, 5 μM
U0126, 30 μMLY294002, 30 μMC2-ceramide or a combination of all 4 inhibitors. (B) Values are a percent of untreated cell
phospo-rpS6 as described in the methods. (Mean+/- SD for n = 3–5). The phosphatase inhibitor Calyculin A (3 nM) was used as
positive control.
https://doi.org/10.1371/journal.pone.0196805.g001
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cytotoxic drug-activated signalling lipid ceramide [26–28] was also inhibitory. In contrast, the
phosphatase inhibitor calyculin A enhanced S6 phosphorylation.
RpS6 dephosphorylation at 4 hours predicts 48 hour drug sensitivity
Data from Fig 1 suggests early changes in rpS6 phosphorylation may be used as a predictor
of chemotherapeutic response in AML cells. To test this hypothesis, 11 AML cell lines were
subjected to 48 hour dose response assays with the following agents: FLT3 inhibitors
(AC220 and sorafenib),[29, 30] DNA double strand break (DSB) inducers (etoposide, GO
and vosaroxin),[31–33] the standard-of-care drug cytarabine and the hsp90 inhibitor
17-AAG.[34]
Using ROC analysis (predictive accuracy test), rpS6 dephosphorylation at 4 hours pre-
dicted the 48 hour response to the DSB inducing drugs etoposide and GO, the FLT3 inhibi-
tors sorafenib and ACC220 as well as to cytarabine (Fig 2 and S1 Table). ROC analysis of 4
hour rpS6 dephosphorylation compared to 48 hour drug sensitivity confirmed that the
assay was highly sensitive and specific with AUC values of 1.0 for etoposide, GO, sorafenib,
AC220 and cytarabine (S1 Fig shows individual ROC curves). An AUC value close to 1 indi-
cates excellent predictive capabilities providing evidence that this laboratory test performed
after 4 hours does have an ability to predict chemosensitivity at 48 hours. For vosaroxin, the
AUC value was 0.82. HL-60 cells, which were sensitive to vosaroxin at 48 hours, did not
dephosphorylate rpS6.
17-AAG, which had been included because of clinical interest in novel hsp90 inhibitors,
[35] was expected to be particularly effective because hsp90 plays a direct role in maintatining
the stability of rpS6.[36] The predictive value for 17-AAG (AUC 0.9) was statistically signifi-
cant, albeit with U937 cells showing confoundingly high dephosphorylation.
PUMA-BH3 peptide-induced cytochrome c release after 4 hours drug
treatment predicts 48 hour drug sensitivity
Dynamic BH3 profiling involves exposing mitochondria to BH3 domain derived peptides fol-
lowing short term drug exposure to prime mitochondria for changes in MOMP as measured
by cytochrome c release. It has been demonstrated that this technique can predict cytotoxicity.
[21] PUMA-BH3 peptide can sensitise all the anti-apoptotic BCL-2 family of proteins [37] and
was used for our assay. To obtain optimal sensitivity with this technique it is important to
establish suitable drug and peptide concentrations so that agent or peptides do not overwhelm
the system by inducing too much cytochrome c release individually. As the technique demands
outer membrane permeabilisation whilst maintaining mitochondrial integrity, we set up
appropriate assay controls and defined their interpretation as>90% induced cytochrome c
release in the presence of a high concentration (10 μM) of the activator peptide BIM-BH3 but
less than 10% when incubated with the non-specific peptide PUMA2A-BH3. PUMA-BH3 pep-
tide-induced cytochrome c release closely predicted the 48 hour IC50 for DSB inducing drugs
and FLT3 inhibitors, with AUC values of 1.0 for etoposide, GO, AC220 and sorafenib (Fig 3
and S1 Table). For vosaroxin, the AUC value was 0.95. As with the rpS6 assay, HL-60 cells,
which were sensitive to vosaroxin at 48 hours, were insensitive in the short-term assay. BH3
profiling was not predictive for responses to 17-AAG, (AUC value 0.63), or cytarabine (AUC
value 0.77). See S2 Fig for individual ROC curves.
Summarising the ROC analysis across the 11 cell lines and 7 drugs (Fig 4), both rpS6
dephosphorylation and dynamic BH3 profiling assays showed highly significant predictive
ability.
Early predictors of AML chemosensitivity
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Fig 2. RpS6 dephosphorylation at 4 hours predicts 48 hour drug sensitivity. (A)MOLM-13 cells were cultured for 4
hours with 100 nM Rapamycin, 1 μM torin1 and 3 μMU0126 to determine p-rpS6 baseline. RpS6 dephosphorylation
after 4 hours culture with 500 nM 17-AAG is also shown. Example histograms are representative of 3 individual
experiments. (B) Based on the 48 hour IC50 values a drug sensitive/resistant cut off for cell lines was determined. Cell
lines were cultured for 4 hours with 1 μM etoposide, 50nM sorafenib, 600ng/ml GO, 10nMAC220, 1 μM vosaroxin,
500nM 17-AAG and 2 μM cytarabine. Values are a percent of untreated cell p-rpS6 as described in the methods. Each
point represents a cell line and is the product of three individual experiments.
https://doi.org/10.1371/journal.pone.0196805.g002
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Changes in expression of apoptotic modulator proteins after four hours
drug exposure
For apoptosis to occur, the effector molecules BAK and BAX oligomerise and form pores that
cause MOMP, resulting in cytochrome c release. Effector molecule activation can be triggered
by the BH3-only proapoptotic BCL-2 family members BIM, BID and PUMA. Prosurvival
members such as MCL-1, BCL-2 and BCL-XL inhibit the BH3-only proteins by sequestration
and hold apoptosis in check. Our dynamic BH3 profiling results clearly demonstrate that
drugs are priming cells to PUMA-BH3 peptide after only 4 hours exposure. We investigated
what effect the drugs were having on BCL-2 apoptotic protein family members during this
time period that might underpin this rapid priming. MV4-11 cells were used as these cells
were the most sensitive cell line to the majority of drugs in our panel (S1 Table). These cells do
not over-express the anti-apoptotic protein BCL-XL.[24] Of the other BCL-2 family prosurvi-
val members MCL-1 has the shorter half-life (approximately 1 hour) and can be rapidly
Fig 3. PUMA-BH3 peptide-induced cytochrome c release after 4 hours drug treatment predicts 48 hour drug sensitivity.
(A)MOLM-13 cells were cultured for 4 hours with 1 μM vosaroxin or 50 nM sorafenib followed by 1 hour treatment with
PUMA-BH3 peptide or PUMA2A control. Example dot plots are representative of 3 individual experiments. (B) Based on the
48 hour IC50 values a drug sensitive/resistant cut off for cell lines was determined as described in the methods. Cell lines were
cultured for 4 hours with 1 μM etoposide, 50nM sorafenib, 600ng/ml GO, 10nM AC220, 1 μM vosaroxin, 500nM 17-AAG or
2 μM cytarabine followed by 1 hour incubation with PUMA-BH3 peptide. Values are corrected for cytochrome c release with
PUMA2A control peptide as described in the methods. Each point represents a cell line and is the product of three individual
experiments.
https://doi.org/10.1371/journal.pone.0196805.g003
Fig 4. ROC curve analysis confirms highly significant overall sensitivity and specificity for the ability of both rpS6
dephosphorylation and PUMA-BH3 induced cytochrome C release after 4 hours drug treatment to predict 48 hour sensitivity
to drugs. Summary ROC curves for percent change in rpS6 phosphorylation and PUMA induced cytochrome c release after 4
hours treatment with 1 μM etoposide, 50nM sorafenib, 600ng/ml GO, 10nM AC220, 1 μM vosaroxin, 500nM 17-AAG or 2 μM
cytarabine in 11 AML cells lines. Cell lines were classified as sensitive or resistant according to 48 hours drug response (The
standardised definition of sensitivity is described in the methods section). Each data point used to generate the analysis is the mean
of three individual experiments.
https://doi.org/10.1371/journal.pone.0196805.g004
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downregulated [38] whilst BCL-2 is a much more stable protein.[37, 39] We used etoposide
and AC220, as DSB-inducing agents and FLT3 inhibitors are of particular clinical interest in
AML: both rpS6 dephosphorylation and dynamic BH3 profiling had been able to predict
response to these drugs (S1 Table). We found that etoposide and AC220 significantly deplete
MCL-1 in the MV4.11 cells without affecting the expression of BCL-2 (Fig 5). The mTORC1
antagonist and translation inhibitor torin1 [40] was included as a control because inhibition of
translation depletes MCL-1.[41] Activation of effector molecules BAK and BAX using confor-
mation-specific antibodies as previously described [24] was not observed (data not shown). Of
the activator BCL-2 family members BID, BIM and PUMA, BIM expression was significantly
increased after 4 hours treatment with AC220 only whilst BID and PUMA were unaffected by
either etoposide or AC220 (Fig 5). See S3 Fig for uncropped blots.
Discussion
This work is a first step towards ascertaining whether short term functional predictive assays
might have clinical application in AML. A history of failure for chemosensitivity assays in clin-
ical practice [3] has been discouraging, but the need for the development of such assays is still
being strongly asserted,[4, 42, 43] with the rationale that molecular assays in unstimulated cells
cannot recapitulate complex behaviour.
We have demonstrated the potential of two same-day functional flow cytometric assays to
predict 48-hour response to chemotherapy in AML cell lines. FLT3 inhibitors are documented
to induce rapid changes in signalling pathways [44–46] and we have shown here that rpS6
dephosphorylation is a suitable indicator of this activity. Early (i.e. less than four hours) pro-
apoptotic changes invoked by DNA damaging drugs are rarely documented. However, in an
exception to the general focus on late changes, Nijhawan and colleagues documented the early
loss of MCL-1 after genotoxic stress, and they included etoposide in their analysis.[47] The
rapidity of ceramide induction following DNA damage [26, 27] and the involvement of cer-
amide in phosphatase activation[48] also encouraged us to postulate that we might be able to
document responses to DNA-damaging agents after four hours. The cell lines were appropri-
ately classified as sensitive or resistant to etoposide and GO. Vosaroxin sensitivity was also pre-
dicted by both assays in 10/11 cell lines.
The main obstacle for further development of this work in clinical samples is that primary
samples are unstable over time in vitro [5] and therefore cannot be used for proof of principle.
Bolt-on studies in the context of clinical trials will be needed to properly evaluate the method-
ologies. Since AML samples can be hypocellular at presentation, the availability of cells can be
a problem for diagnostic assays. Phospho-rpS6 can be performed on very small samples with
minimal cell loss during processing. However, some primary samples have low basal rpS6
phosphorylation.[14] BH3 profiling requires permeabilisation of the outer cell membrane,
while maintaining viable mitochondria: this is technically challenging [22] and the cell require-
ment includes positive and negative controls for permeabilisation as well as no peptide con-
trols for each drug. BIM-BH3 has been used by others for profiling without drugs.[49, 50] Our
choice of PUMA-BH3 rather than BIM-BH3 was made because PUMA gave a more consistent
low baseline level of cytochrome release at a single concentration across several cell lines in
preliminary experiments. In performing the assay in 11 cell lines for this study, we found that
one (M0-91) was hypersentitive to PUMA-BH3 alone (see methods) and the whole assay had
to be repeated with a lower peptide concentration. In summary, BH3 profiling requires more
cells and may also require sample-specific optimisation of baseline conditions. The area under
the curve in Fig 4 was lower for BH3 profiling than for rpS6 phsosphorylation. However,
dynamic BH3 profiling is the more logical assay for early chemosensitivity testing as it takes
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into account apoptosis resistance that might occur separately from or downstream of pRS6
inhibition.
Perturbations of signalling pathways can induce drug resistance mechanisms,[51, 52] but
the finding that rpS6 dephosphorylation at 4 hours was predictive of cell death at 48 hours
implies early, irreversible changes. In the final part of the study we probed for early drug-
induced changes in BCL-2 family proteins that might indicate commitment to apoptosis. Apo-
ptosis is effected by oligomerisation of BAX and BAK and activated by BCL-2 family members
such as BIM, BID and PUMA.[19] The only change we noted in these pro-apoptotic molecules
was induction of BIM by AC220 in sensitive MV4-11 cells (Fig 5). We found significant early
inhibition of MCL-1 by AC220 in these cells (Fig 5). This might be predicated on early down-
regulation of STAT5 signalling: [53] activation of this pathway is documented to maintain
MCL-1 expression.[54] However, MCL-1 was only 20% decreased in etoposide-treated cells.
Given that elimination of MCL1 is reported to be required for the initiation of apoptosis fol-
lowing double strand breaks[47] the delineation of early irreversible pre-apoptotic changes
will likely require attention to post-translational changes and binding partners as well as
expression levels of MCL-1. MCL-1 is sequentially translocated to mitochondria, phosphory-
lated and ubiquitinylated prior to degradation.[55] A possible explanation for the clear-cut
predictive value of the assays in the face of resistance mechanisms is the homogeneity of cell
lines. A future application of the system might be to elucidate whether sensitive and resistant
subsets within patient samples can be defined.
In summary we have described two assays which detect changes occurring in sensitive cells
within four hours of drug application and which predict sensitivity and resistance to DNA
damaging agents and FLT3 inhibitors in a panel of AML cell lines.
Supporting information
S1 Table. Cell line IC50, rpS6 and cytochrome C data. 11 cell lines were treated with 7 differ-
ent drugs or untreated controls for 48 hours to determine an IC50 (nM) (shown in bold;
Fig 5. Changes in expression of apoptotic modulator proteins after four hours drug exposure. (A)MV4-11 cells
were treated for four hours with 1 μM etoposide (E), 10 nM AC220 (A) or 1 μM torin1 (T). Each blot represents one of
three independent experiments. (B) Blots were subjected to densitometry analysis using Image Studio Lite software
(version 5.2). Values shown are percent change in expression normalised to loading control (p =<0.05/p = 0.002/
p = 0.02), analyzed using paired samples t-test, +95% confidence interval. Columns, mean of three experiments;
bars, SD.
https://doi.org/10.1371/journal.pone.0196805.g005
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supscript R = resistant, superscript S = sensitive). Percent rpS6 dephosphorylation (regular
font) and percent PUMA induced cytochrome C release (bold italic) was determined in the
same cell lines after 4 hours drug treatment. Each value is the product of three individual
experiments.
(TIF)
S1 Fig. Individual ROC curves for rpS6 dephosphorylation after 4 hours drug treatment.
ROC curves for percent change in rpS6 phosphorylation after 4 hours treatment with 1 μM
etoposide, 50nM sorafenib, 600ng/ml GO, 10nM AC220, 1 μM vosaroxin, 500nM 17-AAG or
2 μM cytarabine in 11 AML cells lines. Each data point used to generate the analysis is the
mean of three individual experiments.
(TIF)
S2 Fig. Individual ROC curves for PUMA induced cytochrome c release after 4 hours drug
treatment. ROC curves for PUMA induced cytochrome c release after 4 hours treatment with
1 μM etoposide, 50nM sorafenib, 600ng/ml GO, 10nM AC220, 1 μM vosaroxin, 500nM
17-AAG or 2 μM cytarabine in 11 AML cells lines. Each data point used to generate the analy-
sis is the mean of three individual experiments.
(TIF)
S3 Fig. Original uncropped western blots.MV4-11 cells were treated for four hours with
1 μM etoposide, 10 nM AC220 or 1 μM torin1 before probing for the apoptotic modulator pro-
teins Mcl-1, Bcl-2, BIM, PUMA and BID.
(TIF)
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